Inhibition of DNA replication in an Escherichia coli dnaB-22 mutant failed to block quinolone-mediated lethality. Inhibition of protein synthesis by chloramphenicol inhibited nalidixic acid lethality and, to a lesser extent, ciprofloxacin lethality in both dnaB-22 and wild-type cells. Thus, major features of quinolone-mediated lethality do not depend on ongoing replication.
Quinolones are broad-spectrum antibacterials that trap DNA gyrase and DNA topoisomerase IV on DNA as ternary complexes containing double-strand DNA breaks (reviewed in reference 5). The ternary complexes, which block DNA replication (8, 23) , RNA synthesis (13, 24) , and cell growth (7) , lead to cell death by poorly understood processes. Quinolone-mediated inhibition of DNA replication, which is very rapid (19) , is unlikely to account for rapid lethality because inhibition is reversible (4, 8) and because concurrent interruption of RNA or protein synthesis eliminates the lethal action of some quinolones but not their ability to block DNA replication (2, 4) . A different issue is whether ongoing DNA replication is required for quinolone lethality. Such a hypothesis could be derived from studies with other topoisomerases in which collision of replication forks with ternary complexes is thought to release double-strand DNA breaks (3, 21) . To address this possibility with quinolones, we blocked DNA replication by shifting a dnaB mutant of Escherichia coli to nonpermissive temperature. (DnaB is a DNA helicase [11] required for replication fork movement [1] .) Subsequent treatment with quinolone killed the mutant, indicating that ongoing DNA replication is not required.
E. coli strain K12SH-28 and its dnaB-22(Ts) mutant FA22 (6) were obtained from the E. coli Stock Center (Yale University) and were grown at 28°C in M9-glucose minimal medium (14) supplemented with 0.05% Casamino Acids and 1% LB medium (14) . A gyrA quinolone-resistant mutant of FA22, strain KD2672, was constructed by P1-mediated transduction (22) from strain KD2346, a spontaneous ciprofloxacin-resistant derivative of KD1366 (26) that contained GyrA amino acid substitutions Ser-83 to Leu and Asp-87 to Tyr. The dnaB-22 allele was transduced into strain DM4100 (20) using a nearby tetracycline resistance marker (malF-3089:Tn10) to produce strain KD2773. Nalidixic acid, chloramphenicol, and tetracycline were products of Sigma Chemical Co. (St. Louis, MO); ciprofloxacin was obtained from Bayer Corp. (West Haven, CT). Bactericidal activity was determined by incubation in the presence of quinolone followed by dilution and growth on drug-free agar at 28°C for 1 to 2 days. The rate of DNA synthesis was measured by incubating 100 l bacterial culture with 0.1 Ci [ 3 H]thymidine for 2 min followed by determination of acid-precipitable radioactivity.
When the dnaB-22 mutant was grown at 28°C and shifted to 42°C, the rate of DNA synthesis dropped by more than 95% within 10 min and was not inhibited further by subsequent nalidixic acid treatment (not shown). Under these conditions, the viable cell number remained constant for more than 2 h (Fig. 1A) . If nalidixic acid was added to 60 mg/liter 15 min after the shift to 42°C and cultures were incubated for 2 h, the number of viable cells dropped by 100-fold (Fig. 1A) . Under comparable conditions, the parental strain, K12SH-28, grew at 42°C and was also killed by nalidixic acid (Fig. 1A) . The two strains were killed with similar kinetics, although with a long incubation time the mutant was killed slightly faster. For both strains, killing started sooner at 42°C than at 28°C. When the two strains were treated with various concentrations of nalidixic acid for a fixed time (105 min), the dnaB-22 mutant was slightly more susceptible than the wild-type strain at most drug concentrations tested (Fig. 1B) . The slightly greater susceptibility observed with the mutant may reflect a defect in repair or bypass of quinolone-mediated DNA lesions, since the DnaB protein has been implicated in replication fork restart (10, 16) . We established that nalidixic acid kills the dnaB-22 mutant through an interaction with DNA gyrase by treating a dnaB-22 gyrA double mutant (strain KD2672) with nalidixic acid and showing that nalidixic acid failed to kill this strain at either 28°C or 42°C (Fig. 1B) .
We also confirmed that DNA replication has little effect on the role of ongoing protein synthesis in nalidixic acid-mediated lethality. For such a test, dnaB-22 was transferred into a different E. coli strain, since K12SH-28 and FA22 are both hypersusceptible to chloramphenicol, an inhibitor of protein synthesis. The new dnaB-22 strain, KD2773, exhibited temperature-dependent cessation of DNA synthesis, as expected (not shown). When chloramphenicol was added to a culture of strain KD2773 after incubation at 42°C for 5 min, followed by nalidixic acid 10 min later, killing by nalidixic acid was largely inhibited (Fig. 2A) . A similar effect was observed with the parental strain DM4100 (Fig. 2A) . Chloramphenicol protects only partially from lethality due to ciprofloxacin (12), as seen with both the dnaB-22 mutant and the parental strain (Fig.  2B) . Thus, the protective effect of chloramphenicol, which depends on quinolone structure (18) , can be observed when DNA replication is blocked. For reasons that are not understood, reduction of ciprofloxacin-mediated lethality by chloramphenicol was less with the mutant (Fig. 2B) .
Rapid bactericidal action of quinolones is thought to arise from release of double-strand DNA breaks from ternary complexes formed by quinolone, gyrase/topoisomerase IV, and DNA (2, 9). The experiments described above indicate that such a release of DNA breaks is not necessarily caused by collision of replication forks with the complexes because inhibition of replication, through temperature shift of a dnaB-22(Ts) replication mutant, failed to block the lethal action of nalidixic acid (Fig. 1 ). This conclusion is consistent with biochemical studies in which DNA breaks fail to be released by the collision of replication forks with quinolone-topoisomerase IV-DNA complexes (17) . Since a 2-h shift of a dnaC-2 repli- cation-initiation mutant to nonpermissive temperature failed to block the lethal activity of gatifloxacin (not shown), it is unlikely that the loss of dnaB-specific repair causes quinolonemediated cell death when replication is halted. We conclude that replication fork blockage by quinolones is neither necessary nor sufficient for rapid quinolone lethality. Whether lethal chromosome fragmentation is generated by gyrase (2) or by an endonuclease (15, 25) is unknown. Since fluoroquinolones can kill bacteria that are not undergoing DNA or protein synthesis, the possibility exists that some quinolone derivatives may be effective at killing nongrowing cells. Such a finding could have clinical importance for diseases, such as tuberculosis, that are characterized by the presence of persisting cells, since those cells may contribute to relapse and the development of antimicrobial resistance.
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